Sandoz

Unsustainable pricing pressure and abusive patent litigation tactics are just a few factors that can cause market exits which contribute to drug shortages. For over 40 years, generic medicines have improved access for US patients, transforming health outcomes and driving down out-of-pocket costs for millions, but now urgent action is needed to be sure all patients can get the medicines they need, when they need them. Our goal is to ensure uninterrupted access to affordable medicines and make a difference for patients and the US healthcare system – but we cannot do it alone. Sandoz and the Association for Accessible Medicines urge the government to consider the unique aspects that differentiate the brand and generic business models and adopt policies that will reduce drug shortages by improving the long-term sustainability of the generic drug market. What happens next must happen now. Learn more about what Sandoz is doing at www.us.sandoz.com #PioneeringAccess

The passing of the Hatch-Waxman Act in 1984 helped the promise of generic medicines become a reality in the US. Now, forty years later, we sit on the brink of realizing the immense potential of biosimilars to reduce costs and increase access to high-priced biologic treatments in the US. It’s a pivotal moment – and one that is not without its challenges, including misaligned incentives across the US healthcare system that can inflate healthcare costs and restrict patient access to these more affordable alternatives. It’s crucial for stakeholders to advocate for policy changes that promote fair competition and prioritize patient welfare. It is only then that the full potential of biosimilars will be unlocked, ensuring a more sustainable and equitable healthcare system. What happens next must happen now. Learn more about what Sandoz is doing at www.us.sandoz.com #PioneeringAccess

Last week, Sandoz published its very own Generic Sustainability Report – a roadmap for policymakers on the critical changes needed to ensure continued patient access to generic medicines in the US. Have you had a chance to read the report? Share your thoughts in the comments below. Learn more here: https://bit.ly/3XUNW7q #genericmedicines #patientaccess

Without immediate action, we could face a reality where shortages of drugs for critical, acute, and chronic conditions, alike, are increasingly common – not to mention, the U.S. will leave billions of dollars in healthcare savings on the table. There is an urgent need to advance pragmatic solutions to mitigate these issues and support the sustainable implementation of generic medicines in service for patients today, and to ensure stronger healthcare systems of the future. We are committed to working together with stakeholders and policymakers to overcome existing barriers impacting the availability of generics, ensure reliability in manufacturing and consistent access to high-quality medicines for all patients, and supporting the long-term sustainability of our nation’s health care systems. But we cannot do it alone. What happens next must happen now. Learn more about what Sandoz is doing at www.US.sandoz.com #sandoz #PioneeringAccess

In today's dynamic and ever-evolving world, continuous learning and personal growth are key. #Sandoz is working to help colleagues like Camila Dias Gomes unlock their full potential and achieve their professional aspirations. As we collectively build the Sandoz of the future, we will continue to prioritize the personal and professional growth of all Sandoz colleagues. Learn more: https://lnkd.in/evdXGjtY #SandozLife #PersonalGrowth

Biosimilar medicines can help healthcare systems expand patient access to innovative biologics while generating vital cost savings. However, many critical biologics set to lose exclusivity currently do not have a biosimilar candidate in the pipeline. In an opinion piece with the European Pharmaceutical Review, our Global Head Biosimilars and Country President Austria, Peter Stenico, discusses the importance of addressing this 'biosimilar void'. Peter explains that by creating a favorable environment for biosimilars in Europe, we can attract more competition and help healthcare systems deliver on the rising demand for high-quality care while managing costs. To learn more, read Peter's article in full in EPR's latest Pharma Horizons report:  https://lnkd.in/eX-aqeJf #Sandoz #Biosimilars #PioneeringAccess 

Forty years ago today, the Hatch-Waxman Act was signed into law, creating the pathway that made high-quality, lower-cost generic medicines widely available in the US. In fact, 9 out of 10 prescriptions filled are for generic medicines - but access to these critical therapies is in jeopardy due to ongoing drug shortages. Sandoz developed a report identifying the root causes of generic drug shortages in the US and outlining key solutions for a sustainable, patient-centric supply chain. Read more on this here: https://bit.ly/3XUNW7q #genericmedicines #patientaccess

Generic and biosimilar drugs play a critical role in the U.S. healthcare system, saving patients billions of dollars every year on prescription medicines. This is in large part due to the passing of the Hatch-Waxman Act, which helped speed the introduction of these important medicines to the U.S. market. Unnecessary litigation costs induced by brand drug manufacturers delay and even prevent (or discourage) generic manufacturers from developing and launching less expensive generic medicines. This results in higher priced brand medicines remaining on the market longer than patents protect, fewer generic competitors and potential drug shortages, ultimately harming patients. What happens next must happen now. #Sandoz #PioneeringAccess

Our #Sandoz team is attending the One Young World Summit 2024! 🌍 Ten Sandoz delegates will be connecting with global leaders and young changemakers to explore new ideas and drive impactful solutions in healthcare and sustainability. Their passion and commitment to making healthcare more accessible and equitable is inspirational, and their fresh perspectives will help shape the future of healthcare 💡 #OYW2024 #SandozLife James Board, Chet Eckman, Brigitte Richard, Keitumetse Motaung, Manuela Bieli, Anna Geisler, Ognen J., Ana Kogan Wais, Shreya gupta, Paul Walz

Our own Dr. Boumediene Soufi, Global AMR Program Lead, is participating in the 79th session of the UN General Assembly (UNGA 79), actively contributing to key sessions on antimicrobial resistance (AMR) and other critical global health issues. As the global leader in generic and biosimilar medicines, #Sandoz is committed to advancing its Purpose of pioneering access for patients. Engaging in these important global discussions with key stakeholders allows us to contribute to promoting responsible antibiotic use and fostering cross-sector collaboration to tackle the global health threat posed by AMR. Together, we are working towards a future where access to affordable and high-quality medicines is ensured for all and the global healthcare community unites to combat global public health threats, particularly #AMR. #UNGA79